ASTCT

#CEC24 is only one week away! APPs, nurses, fellows & in-training professionals — don’t miss out on this opportunity to learn from experts in the field in sessions made for you. Register now to join us in St. Louis: https://ow.ly/ei2h50TpC5O

Our new infographic series turns the "Best of CAR T at the 2024 Tandem Meetings" webinar series from into digestible graphics for reading and sharing. View the new infographics on Nucleus: https://ow.ly/uxfO50T6EA1

Learn how your organization/institution can implement and operate a successful immune effector cell therapy program in this webinar from ASTCT's Payor Relations Committee. Register now to join us on Oct. 10: https://ow.ly/jYsN50TzlMw

?? Ready to tackle the complexities of #HCT and cellular gene therapy toxicities? Join experts at the Toxicities Conference! ???? Whether in person or virtually, this is a must-attend event for healthcare professionals managing these challenges. ?? Register now: https://ow.ly/O3PG50TBR4c

Created with content from our Best of CAR T at #Tandem24 webinar series, this infographic features #CARTcells + late effects, including secondary malignancies. View the full series of infographics: https://ow.ly/wcGC50T6EHQ

The study AMpLify, seeks to assess the safety, tolerability & preliminary efficacy of CB-012, which targets the C-type lectin-like molecule-1 (CLL-1) antigen, selectively expressed on AML cells but absent on hematopoietic stem cells. This specificity is intended to minimize collateral damage to healthy cells, a common hurdle in CAR-T cell therapies for AML. Read more on Nucleus: https://ow.ly/lRAr50TBRnL

In a special co-branded episode between Cancer Network Oncology On the Go + ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy. Listen now: https://ow.ly/Letx50TpC9N

?? Calling all researchers! Submit your abstracts and share your cutting-edge research in #HCT, cell & gene therapy with more than 5,000 professionals at #Tandem25 in Hawaii. ?? @CIBMTR ?? Deadline: October 9, 2024 ?? https://lnkd.in/gadWB2vi

Stay at the forefront of transplantation and cellular therapy in 2024! Renew your ASTCT membership today to maintain access to essential resources like ASTCT's journal, exclusive communities and discounted meeting registrations through 2025. ?? Renew: https://ow.ly/NqvB50TBR7v

Learn how your organization/institution can implement and operate a successful immune effector cell therapy program in this webinar from ASTCT's Payor Relations Committee. Register now to join us on Oct. 10: https://ow.ly/jYsN50TzlMw